Previous 10 | Next 10 |
CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ: MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today an...
Mersana Therapeutics (NASDAQ:MRSN) is up 14% in early Wednesday trading after the filing from last night discloses ~$5M worth of insider buying. Director Andrew Hack has bought 1,136,363 shares of the company at an average price of $4.42 each, as per the SEC filing. The transaction ...
Gainers:Enphase Energy ENPH +16%. Tritium DCFC (NASDAQ:DCFCW) +12%. Leafly Holdings LFLY +11%. Tritium DCFC Limited DCFC +9%. Mersana Therapeutics (NASDAQ:MRSN) +8%. Losers: Varex Imaging VREX -14%. QuinStreet QNST -10%. Ichor Holdings ICHR -6%. ...
Gainers: BioCardia BCDA +32%. Biophytis BPTS +17%. Mersana Therapeutics MRSN +7%. Liquidia (NASDAQ:LQDA) +5%. Vaccitech (NASDAQ:VACC) +3%. Losers: Kiromic BioPharma KRBP -17%. Mainz Biomed (NASDAQ:MYNZ) -9%. Vaccinex (NASDAQ:VCNX) -7%. NeuroBo Phar...
Mersana Therapeutics (NASDAQ:MRSN) is trading ~7% higher in the pre-market after announcing a research collaboration and license agreement with Janssen Biotech of Johnson & Johnson (NYSE:JNJ) to develop antibody-drug conjugates for three targets. Per the terms, Janssen will deli...
BioCardia (NASDAQ:BCDA) +32% receives FDA breakthrough device designation for CardiAMP cell therapy system for heart failure. Bon Natural Life (NASDAQ:BON) +29% on FY results. Lightning eMotors (NYSE:ZEV) +19% after electrification deal with General Motors. Redwire (NYSE:RDW) +...
Collaboration focused on discovering novel ADCs for three targets by leveraging Mersana’s ADC expertise and the Dolasynthen platform with Janssen’s proprietary antibodies Mersana receives $40 million upfront payment and potentially more than $1 billion in total...
UPLIFT, a single-arm registrational trial of UpRi in platinum-resistant ovarian cancer, expected to complete enrollment in Q3 2022 UP-NEXT, a Phase 3 trial of UpRi monotherapy maintenance in platinum-sensitive ovarian cancer, expected to initiate in Q2 2022 Interim data ...
CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ: MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announce...
CAMBRIDGE, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announce...
News, Short Squeeze, Breakout and More Instantly...
Mersana Therapeutics Inc. Company Name:
MRSN Stock Symbol:
NASDAQ Market:
Mersana Therapeutics Inc. Website:
Maximum tolerated dose not yet established in Phase 1 clinical trial of XMT-1660; enrollment in dose escalation and backfill cohorts continuing in parallel; expect to announce initial clinical data and initiate expansion in the second half of 2024 Patient recruitment ongoing in Phase 1 cl...
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that ...
2024-03-18 08:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...